Smoking Addiction - Pipeline Review, H1 2017

  • ID: 4311825
  • Report
  • 86 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aradigm Corp
  • Bioprojet SCR
  • CoMentis Inc
  • Invion Ltd
  • Johnson & Johnson
  • NAL Pharmaceuticals Ltd
  • MORE
Smoking Addiction - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aradigm Corp
  • Bioprojet SCR
  • CoMentis Inc
  • Invion Ltd
  • Johnson & Johnson
  • NAL Pharmaceuticals Ltd
  • MORE
  1. Introduction
  2. Smoking Addiction - Overview
  3. Smoking Addiction - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Smoking Addiction - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Smoking Addiction - Companies Involved in Therapeutics Development
  15. Aradigm Corp
  16. Bionex Pharmaceuticals LLC
  17. Bioprojet SCR
  18. CoMentis Inc
  19. Embera NeuroTherapeutics Inc
  20. Invion Ltd
  21. Jeil Pharmaceutical Co Ltd
  22. Johnson & Johnson
  23. Lotus Pharmaceutical Co Ltd
  24. NAL Pharmaceuticals Ltd
  25. Pfizer Inc
  26. Rock Creek Pharmaceuticals, Inc.
  27. Selecta Biosciences Inc
  28. Sopharma AD
  29. Zynerba Pharmaceuticals Inc
  30. Smoking Addiction - Drug Profiles
  31. (metyrapone + oxazepam) - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. AKR-214 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. amitifadine - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. Anatabine - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. AT-1001 - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. BP-1.4979 - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. cytisine - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. GTS-21 - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. JLP-1603 - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. JNJ-39393406 - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. nadolol - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. NFL-101 - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. NIC-7DT - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. nicotine - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. nicotine bitartrate - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. nicotine bitartrate - Drug Profile
  92. Product Description
  93. Mechanism Of Action
  94. R&D Progress
  95. PF-06413367 - Drug Profile
  96. Product Description
  97. Mechanism Of Action
  98. R&D Progress
  99. SEL-068 - Drug Profile
  100. Product Description
  101. Mechanism Of Action
  102. R&D Progress
  103. SEL-070 - Drug Profile
  104. Product Description
  105. Mechanism Of Action
  106. R&D Progress
  107. Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
  108. Product Description
  109. Mechanism Of Action
  110. R&D Progress
  111. Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile
  112. Product Description
  113. Mechanism Of Action
  114. R&D Progress
  115. Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile
  116. Product Description
  117. Mechanism Of Action
  118. R&D Progress
  119. Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
  120. Product Description
  121. Mechanism Of Action
  122. R&D Progress
  123. Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
  124. Product Description
  125. Mechanism Of Action
  126. R&D Progress
  127. Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
  128. Product Description
  129. Mechanism Of Action
  130. R&D Progress
  131. URB-694 - Drug Profile
  132. Product Description
  133. Mechanism Of Action
  134. R&D Progress
  135. Vaccine for Smoking Addiction - Drug Profile
  136. Product Description
  137. Mechanism Of Action
  138. R&D Progress
  139. Smoking Addiction - Dormant Projects
  140. Smoking Addiction - Discontinued Products
  141. Smoking Addiction - Product Development Milestones
  142. Featured News & Press Releases
  143. May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
  144. Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
  145. Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet
  146. Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
  147. Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
  148. Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
  149. Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
  150. Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
  151. Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
  152. Jan 29, 2014: FDA clears path for “Smoking Cessation” clinical trial of INV102 (nadolol)
  153. Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
  154. Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
  155. Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
  156. Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
  157. Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
  158. Appendix
  159. Methodology
  160. Coverage
  161. Secondary Research
  162. Primary Research
  163. Expert Panel Validation
  164. Contact Us
  165. Disclaimer
List of Tables:
  1. Number of Products under Development for Smoking Addiction, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Mechanism of Action, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Smoking Addiction - Pipeline by Aradigm Corp, H1
  13. Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1
  14. Smoking Addiction - Pipeline by Bioprojet SCR, H1
  15. Smoking Addiction - Pipeline by CoMentis Inc, H1
  16. Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1
  17. Smoking Addiction - Pipeline by Invion Ltd, H1
  18. Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H1
  19. Smoking Addiction - Pipeline by Johnson & Johnson, H1
  20. Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H1
  21. Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H1
  22. Smoking Addiction - Pipeline by Pfizer Inc, H1
  23. Smoking Addiction - Pipeline by Rock Creek Pharmaceuticals, Inc., H1
  24. Smoking Addiction - Pipeline by Selecta Biosciences Inc, H1
  25. Smoking Addiction - Pipeline by Sopharma AD, H1
  26. Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1
  27. Smoking Addiction - Dormant Projects, H1
  28. Smoking Addiction - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Smoking Addiction, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aradigm Corp
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • CoMentis Inc
  • Embera NeuroTherapeutics Inc
  • Invion Ltd
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Lotus Pharmaceutical Co Ltd
  • NAL Pharmaceuticals Ltd
  • Pfizer Inc
  • Rock Creek Pharmaceuticals, Inc.
  • Selecta Biosciences Inc
  • Sopharma AD
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll